Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2007

View Archived Issues

Novel treatment options for gastrointestinal disorders reported in recent patents

Novel diagnostic agents disclosed by Fujifilm, INSERM and Cedex

Amgen acquires Ilypsa and late-stage selective phosphate binder

Arena's phase I APD-791 trial for arterial thrombosis commences

Interim data from Bone Medical's phase II trial of Capsitonin capsules

DOR begins patient enrollment for phase II trial of orBec for acute GVHD prevention

Affiris commences phase I trial of Alzheimer's vaccine AD-01

EpiCept and Dalhousie University sign licensing agreement for EpiCept NP-1

Gilead Sciences reports results for the second quarter 2007

Low allergy symptom levels confound phase III PreHistin findings

Arpida acquires TLT Medical

Glenmark acquires CHR-1103 and CHR-1201

Mpex begins phase Ib multidose trial of MP-376 for CF

Positive interim results from Peplin's phase IIb study of PEP-005 for AK

EMEA approval of Genta's MAA for Genasense requires additional trial

Genzyme completes phase III trial of Mozobil for NHL

MedImmune initiates phase Ib trial of MEDI-545 for lupus

Abbott submits regulatory filings for lower-strength Kaletra/Aluvia tablet

Preclinical characterization of phase II antiinflammatory compound CJ-023423 from Pfizer

Positive opinion in Europe for smaller capsules of Tamiflu

First-in-human trial of MLN-8237 under way

Phase I/II trial of PMEG prodrug scheduled to begin this month

New analgesics disclosed in recent patent literature

Preclinical antiglaucomal efficacy of the novel prostanoid FP receptor agonist tafluprost presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...